CN109906227A - 8,9-二氢咪唑[1,2-a]嘧啶并[5,4-e]嘧啶-5(6H)-酮类化合物 - Google Patents

8,9-二氢咪唑[1,2-a]嘧啶并[5,4-e]嘧啶-5(6H)-酮类化合物 Download PDF

Info

Publication number
CN109906227A
CN109906227A CN201780068490.0A CN201780068490A CN109906227A CN 109906227 A CN109906227 A CN 109906227A CN 201780068490 A CN201780068490 A CN 201780068490A CN 109906227 A CN109906227 A CN 109906227A
Authority
CN
China
Prior art keywords
pyrimidine
amino
pyrimido
phenyl
glyoxalidine simultaneously
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780068490.0A
Other languages
English (en)
Other versions
CN109906227B (zh
Inventor
蔡遂雄
田野
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Impact Therapeutics Inc
Original Assignee
Impact Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201710440456.3A external-priority patent/CN109020981A/zh
Application filed by Impact Therapeutics Inc filed Critical Impact Therapeutics Inc
Publication of CN109906227A publication Critical patent/CN109906227A/zh
Application granted granted Critical
Publication of CN109906227B publication Critical patent/CN109906227B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本发明提供8,9‑二氢咪唑[1,2‑a]嘧啶并[5,4‑e]嘧啶‑5(6H)‑酮类化合物。具体而言，本发明提供式(I)的化合物，或其可药用盐或前药：式(I)中A和R1‑R7为本文所定义。式(I)的化合物是Wee1激酶抑制剂。因此，本发明的化合物可用于治疗由Weel活性异常而导致的疾病。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN201780068490.0A 2016-11-16 2017-11-16 8,9-二氢咪唑[1,2-a]嘧啶并[5,4-e]嘧啶-5(6H)-酮类化合物 Active CN109906227B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2016110098274 2016-11-16
CN201611009827 2016-11-16
CN2017104404563 2017-06-12
CN201710440456.3A CN109020981A (zh) 2017-06-12 2017-06-12 8,9-二氢咪唑[1,2-a]嘧啶并[5,4-e]嘧啶-5(6H)-酮类化合物
PCT/CN2017/111230 WO2018090939A1 (zh) 2016-11-16 2017-11-16 8,9-二氢咪唑[1,2-a]嘧啶并[5,4-e]嘧啶-5(6H)-酮类化合物

Publications (2)

Publication Number Publication Date
CN109906227A true CN109906227A (zh) 2019-06-18
CN109906227B CN109906227B (zh) 2022-03-11

Family

ID=62145906

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780068490.0A Active CN109906227B (zh) 2016-11-16 2017-11-16 8,9-二氢咪唑[1,2-a]嘧啶并[5,4-e]嘧啶-5(6H)-酮类化合物

Country Status (9)

Country Link
US (2) US10703759B2 (zh)
EP (1) EP3543242B1 (zh)
JP (1) JP7240784B2 (zh)
KR (1) KR102534962B1 (zh)
CN (1) CN109906227B (zh)
AU (1) AU2017359844B2 (zh)
CA (1) CA3043945A1 (zh)
ES (1) ES2968252T3 (zh)
WO (1) WO2018090939A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115073460A (zh) * 2022-07-13 2022-09-20 苏州施安鼎泰生物医药技术有限公司 一种嘧啶并[5,4-c][2,6]萘啶衍生物及其制备方法以及药物组合物和应用
CN115448921A (zh) * 2021-06-08 2022-12-09 四川大学 一类咪唑烷并嘧啶酮化合物及在治疗HsClpP介导的疾病中的用途

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018347307A1 (en) 2017-10-09 2020-04-23 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
WO2019074979A1 (en) 2017-10-09 2019-04-18 Girafpharma, Llc HETEROCYCLIC COMPOUNDS AND USES THEREOF
CN112771049B (zh) 2018-09-27 2024-01-26 贝达药业股份有限公司 Fgfr4抑制剂及其应用
KR20210141659A (ko) 2019-03-22 2021-11-23 쇼우야오 홀딩스 (베이징) 코., 엘티디. Wee1 억제제 및 이의 제조 및 용도
EP3952877A4 (en) 2019-04-09 2022-12-14 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND USES THEREOF
US20220162229A1 (en) * 2019-04-09 2022-05-26 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
EP3952878A4 (en) * 2019-04-09 2023-01-04 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND USES THEREOF
US20240010655A1 (en) * 2019-10-16 2024-01-11 Impact Therapeutics (Shanghai), Inc Dihydroimidazo pyrimido pyrimidinone compound
CN117202908A (zh) * 2021-03-10 2023-12-08 上海瑛派药业有限公司 Wee1激酶抑制剂在治疗癌症疾病中的应用
CA3237756A1 (en) * 2021-11-09 2023-05-19 Hangzhou Glubio Pharmaceutical Co., Ltd. Wee1 protein kinase degradation agent and use thereof
WO2023093840A1 (en) * 2021-11-26 2023-06-01 Impact Therapeutics (Shanghai) , Inc Use of wee1 kinase inhibitors in the treatment of cancer
CN116462687A (zh) 2022-01-18 2023-07-21 江苏天士力帝益药业有限公司 Wee1抑制剂及其制备和用途
WO2023170065A1 (en) * 2022-03-07 2023-09-14 Debiopharm International S.A. Methods of treating small cell lung cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005021551A1 (en) * 2003-08-27 2005-03-10 Amgen Inc. Substituted heterocyclic compounds and methods of use
CN1646529A (zh) * 2002-04-03 2005-07-27 霍夫曼-拉罗奇有限公司 咪唑并稠合化合物
CN103570731A (zh) * 2012-07-30 2014-02-12 中国科学院广州生物医药与健康研究院 嘧啶并三环或嘧啶并四环类化合物及其药用组合物和应用
CN103703005A (zh) * 2011-02-28 2014-04-02 艾伯维公司 激酶的三环抑制剂
CN105829315A (zh) * 2013-12-19 2016-08-03 阿尔麦克探索有限公司 可用作Wee-1激酶抑制剂的嘧啶并嘧啶酮类

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4444762A (en) 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1646529A (zh) * 2002-04-03 2005-07-27 霍夫曼-拉罗奇有限公司 咪唑并稠合化合物
WO2005021551A1 (en) * 2003-08-27 2005-03-10 Amgen Inc. Substituted heterocyclic compounds and methods of use
CN103703005A (zh) * 2011-02-28 2014-04-02 艾伯维公司 激酶的三环抑制剂
CN103570731A (zh) * 2012-07-30 2014-02-12 中国科学院广州生物医药与健康研究院 嘧啶并三环或嘧啶并四环类化合物及其药用组合物和应用
CN105829315A (zh) * 2013-12-19 2016-08-03 阿尔麦克探索有限公司 可用作Wee-1激酶抑制剂的嘧啶并嘧啶酮类

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YUNSONG TONG ET AL.: ""Pyrimidine-Based Tricyclic Molecules as Potent and Orally Efficacious Inhibitors of Wee1 Kinase"", 《ACS MEDICINAL CHEMISTRY LETTERS》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115448921A (zh) * 2021-06-08 2022-12-09 四川大学 一类咪唑烷并嘧啶酮化合物及在治疗HsClpP介导的疾病中的用途
WO2022257581A1 (zh) * 2021-06-08 2022-12-15 四川大学 一类咪唑烷并嘧啶酮化合物及其在治疗HsClpP介导的疾病中的用途
CN115448921B (zh) * 2021-06-08 2023-08-01 四川大学 一类咪唑烷并嘧啶酮化合物及在治疗HsClpP介导的疾病中的用途
CN115073460A (zh) * 2022-07-13 2022-09-20 苏州施安鼎泰生物医药技术有限公司 一种嘧啶并[5,4-c][2,6]萘啶衍生物及其制备方法以及药物组合物和应用

Also Published As

Publication number Publication date
CN109906227B (zh) 2022-03-11
US20200385394A1 (en) 2020-12-10
EP3543242B1 (en) 2024-01-03
KR20190099209A (ko) 2019-08-26
CA3043945A1 (en) 2018-05-24
EP3543242A4 (en) 2020-04-15
US20190308984A1 (en) 2019-10-10
ES2968252T3 (es) 2024-05-08
JP7240784B2 (ja) 2023-03-16
JP2020502065A (ja) 2020-01-23
US10703759B2 (en) 2020-07-07
EP3543242C0 (en) 2024-01-03
AU2017359844B2 (en) 2021-09-30
EP3543242A1 (en) 2019-09-25
US11345711B2 (en) 2022-05-31
AU2017359844A1 (en) 2019-06-27
KR102534962B1 (ko) 2023-05-22
WO2018090939A1 (zh) 2018-05-24

Similar Documents

Publication Publication Date Title
CN109906227A (zh) 8,9-二氢咪唑[1,2-a]嘧啶并[5,4-e]嘧啶-5(6H)-酮类化合物
JP5926727B2 (ja) 置換イミダゾ［１，２−ｂ］ピリダジン
JP5830094B2 (ja) 置換イミダゾ［１，２−ａ］ピリミジンおよび−ピリジン
JP4845379B2 (ja) サイクリン依存性キナーゼインヒビターとしてのイミダゾピリジン
EP2773623B1 (en) 1-(arylmethyl)-5,6,7,8-tetrahydroquinazoline-2,4-diones and analogs and the use thereof
CN114057771B (zh) 大环化合物及其制备方法和应用
TW201245161A (en) 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof
CN110167941A (zh) 取代的稠合杂芳基化合物作为激酶抑制剂及其应用
Zhang et al. Design, synthesis and evaluation of novel 7H-pyrrolo [2, 3-d] pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis
WO2019011228A1 (zh) 咪唑并[1,2-b]嘧啶并[4,5-d]哒嗪-5(6H)-酮类化合物及其应用
JP2016508135A (ja) カゼインキナーゼ１ｄ／ｅ阻害剤としての新規なピラゾール置換のイミダゾピラジン
JP2022547294A (ja) キナーゼ阻害剤としての３，５－ジ置換ピラゾール化合物およびその応用
CA3214900A1 (en) Carboxamide pyrolopyrazine and pyridine compounds useful as inhibitors of myt1 and use thereof in the treatment of cancer
CN110312717A (zh) 取代的稠合杂芳三环化合物作为激酶抑制剂及其应用
CN114502559B (zh) 二氢咪唑并嘧啶并嘧啶酮类化合物
CN109020981A (zh) 8,9-二氢咪唑[1,2-a]嘧啶并[5,4-e]嘧啶-5(6H)-酮类化合物
JP2016537384A (ja) ピロロピロロン誘導体およびｂｅｔ阻害剤としてのその使用
CA3235663A1 (en) Substituted triazoloheteroaryl compounds as usp1 inhibitors and the use thereof
JP2013530250A (ja) 二環式ピリミジン化合物
CN117412973A (zh) 含氮稠合杂芳双环化合物作为usp1抑制剂及其应用
CN116670134A (zh) 取代的咪唑并[1,5-b]哒嗪化合物作为激酶抑制剂及其应用
WO2014040373A1 (zh) PI3K和/或mTOR抑制剂
JP2022548055A (ja) 置換イミダゾキノキサリン化合物およびその応用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant